The agreement will give each company’s investors roughly 50% ownership of the combined entity, which will be listed on the New York Stock Exchange, Mallinckrodt and Endo said Thursday in a
Both drugmakers — previously active acquirers in the heyday of large specialty pharmaceutical deals — have emerged from bankruptcies and faced litigation tied to the US opioid crisis in recent ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.